
Biologics Symposium 2026 – Dutch edition:
Designing tomorrow’s therapies
Location: Accelerator Building - Utrecht
Date: June 2
Free to attend*
About Biologics Symposium 2026
Advanced biologics are reshaping therapeutic innovation, combining engineered proteins, antibodies, and cellular approaches to target disease with exceptional precision. The Netherlands hosts one of Europe’s most dynamic and collaborative immunotherapy ecosystems, making it an ideal setting to connect with leading experts and innovative companies.
Together we will explore:
• Early characterization strategies that reduce downstream surprises
• Innovative biologics platforms for oncology and beyond
• Emerging targets and new mechanism of action
• Novel antibody formats and functional profiling of mono- and multi-specific antibodies
Come for the insights. Stay for the conversations that move programs forward.


Joost Uitdehaag

Agapitos Patakas, PhD

Ilse Roodink, PhD

Madelon Maurice

Lars Guelen, PhD

Erik Doevendans

Maurits den Boer
.png)
Renier Heijkants
.png)
Kristof Vercruysse
.png)
Jan-Jaap Verhoef
.png)
Néstor Vázquez Bernat
.png)
Marleen van Loenen

Jana Obajdin

Floris Hamel

Charlotte Koldeweij

Adele Hannigan

Valentina Vignali
How to get to the venue
Getting to The Accelerator
Address: Uppsalalaan 17, 3584 CT Utrecht
- By tram (fastest from Utrecht Central Station): Take Tram 22 toward P+R Science Park and get off at the final stop. The building is a 3‑minute walk back toward the city.
- By bus: Take Bus 28 toward P+R Science Park and exit at the final stop.
- By bicycle: A 15–20 minute ride from Utrecht city centre; secure bike parking is available at the building entrance.
- By car: From the A28, take Exit 2 (Utrecht Science Park). Parking is available at P+R Science Park (Uppsalalaan 7), directly adjacent to the venue.

RoukenBio - Immunology CRO redefined is providing discovery to IND-enabling immunology and bioassay research services to a global customer base in the therapeutic areas of inflammation, auto-immunity, immuno-oncology, oncology and beyond. Our vision is to become the most trusted research partner for biotherapeutic innovators.
Backed by our brilliant minds, we have turned the traditional CRO model on its head by fostering a collaborative and personalised approach.
Our mission is simple: Solve problems. Deliver quality data. Propel your drug discovery breakthroughs.

AVS Bio is a global company supporting the development of biologics for animal and human health with products and services at its operational sites in North America and Europe.
AVS Bio offers design-driven antibody discovery and development services, tailored to target insights and lead antibody requirements. Since 2018, AVS Bio has supported more than 100 life sciences companies launch successful lead antibody programs, including the development of 10 antibodies that entered clinical trials.
AVS Bio completed over 3,250 standalone protein production and purification programs over the past decades.
Our clients trust us for our expertise, efficiency, and commitment to turning complex challenges into successful outcomes.
* Registration is open exclusively to therapeutic developers and academics. If you do not fall into these categories, please email hello@rouken.bio to request permission to attend.



.png)

